ライフサイエンスコーパス: phage display

1 olation of antibodies from rats using immune phage display.

2 immunoreagents are generated using antibody-phage display.

3 d by immunoblot and by epitope mapping using phage display.

4 internalized by cells, designated z13, using phage display.

5 ctivities by expressing Evasin mutants using phage display.

6 ted TUPS among peptide sequences selected by phage display.

7 scovery of new peptides and proteins through phage display.

8 ression markers or peptides discovered using phage display.

9 ovo G4-binding bicyclic peptides selected by phage display.

10 phopeptide binding specificities in vitro by phage display.

11 eatly expands the chemical space amenable to phage display.

12 nant gluten epitope DQ2.5-glia-alpha1a using phage display.

13 was identified with the use of programmable phage display.

14 irs of recombinant affinity reagents through phage-display.

15 Here, using phage display affinity maturation, we developed a high-a

16 selected broadly neutralizing nanobodies by phage display after immunization of dromedaries with dif

17 d from a minimalist synthetic library during phage display against a branched RNA target.

18 Phage display against D-VEGF-A was used to screen design

19 antibodies generated from large libraries by phage display against important human antigen targets, w

20 Here we used phage display against virus-like particles (VLPs) to iso

21 Phage display allows material scientists to design speci

22 M13 phage displaying an in vivo biotinylatable peptide (AviT

23 which were known to interact with USP2 from phage display analysis.

24 s encoded by mRNA, followed by two rounds of phage display and binder identification by ELISA.

25 Candidate peptides were identified by phage display and deep sequencing, and hits were charact

26 on-antibody binding proteins against GPC3 by phage display and developed a new sandwich chemiluminesc

27 Here we describe a system that combines phage display and efficient mammalian expression in a si

28 ral monoclonal antibodies were isolated from phage display and hybridoma platforms by functional scre

29 roteome of pancreatic cancer endothelium via phage display and identify hornerin as a critical protei

30 Monoclonal antibody technologies, phage display and mRNA display, are methods that could b

31 he analysis of DUBs that are recalcitrant to phage display and other in vitro methods.

32 We employed substrate phage display and positional proteomics to compare subst

33 receptor ectodomain have been discovered by phage display and reported in the literature.

34 icular Ub-specific proteases (USPs) and used phage display and saturation scanning mutagenesis to com

35 from a large synthetic antibody library with phage display and used to develop a single-step sandwich

36 protein libraries, screened them in vitro by phage display, and analyzed their response to selection

37 By combining genetic immunization, phage display, and biopanning, we identified two functio

38 ibe the use of computational protein design, phage display, and high-throughput binding assays to cre

39 HS-specific phage display antibodies (HS3A8 and RB4EA12) showed sign

40 ndependently of the surrounding scaffold, as phage display antibody libraries using these scaffolds y

41 oth HT-2 and T-2 toxins was developed from a phage display antibody library containing 6 x 10(7) diff

42 the anti-Dsg3 IgG(+) repertoire by antibody phage display (APD) and PCR indicated that six clonal li

43 a foundation to further expand the scope of phage display applications.

44 Here, using in vivo phage display approach and the partial carotid ligation

45 To improve binding affinity, we used a phage display approach by randomizing seven PCSK9 contac

46 We describe a phage display approach that we have previously used to g

47 We used a phage display approach to identify synthetic antibodies

48 A phage display approach was herein used to select motifs

49 tumor penetrating peptides identified using phage display are not known.

50 c screening, whole exome sequencing, and the phage-display assay, VirScan, for viral immune responses

51 Through phage display-based functional proteomics, immunohistoch

52 Thus, using a gene fragment- and phage display-based pipeline, we have identified and val

53 Using a phage display-based whole cell biopanning procedure, we

54 tegration of enzymatic processing steps into phage display biopanning to expand the biocombinatorial

55 Phage display biopanning with Illumina next-generation s

56 From an initial phage display biopanning, a series of peptide ligands fo

57 that high-throughput sequencing can empower phage display by (i) enabling the analysis of complex bi

58 e we show that bicyclic peptides isolated by phage display can target the E2 binding sites on the HEC

59 a high-throughput method, we developed a T7 phage display cDNA library derived from mRNA isolated fr

60 In brief, random peptides were encoded by phage display, chemically cyclized with an azobenzene li

61 Using phage display combined to rational design, we developed

62 In this study, we used a phage display complementary DNA library screening strate

63 Here we demonstrate the use of lambda-phage displaying Cry1Aa13 toxin variants modified in dom

64 croarray data and shows utility in analyzing phage display datasets.

65 Phage display empowered the development of proteins with

66 We have developed a phage display engineering strategy to generate synthetic

67 and MCP are ideally positioned for DGR-based phage-display engineering.

68 s of WWOX, we employed mass spectrometry and phage display experiments to identify putative WWOX-inte

69 oviding suitable starting points for seeding phage display experiments.

70 rectional promoter (GBid) - for constructing phage display Fab libraries.

71 entified from an MAA-enriched umbilical cord phage displayed Fab library, and a derived Fab with the

72 uman monoclonal antibodies (mAbs) from large phage-displayed Fab, scFv, and VH libraries by panning a

73 ement of metastatic prostate cancer, we used phage display fingerprinting to analyze sequentially acq

74 s, alternative methods such as comprehensive phage display, fluid-phase immunoassays, and antigen mic

75 to systematically evaluate nAbs isolated by phage display for effective and specific use as intrabod

76 hetic antibody-fragment (Fab) library in the phage-display format and isolated antibody-fragments tha

77 ecificity and affinity, were retrieved after phage display from a large 'immune' library constructed

78 t-based discovery (GE-FBD) uses selection of phage-displayed glycopeptides to dock a glycan fragment

79 e role that combinatorial approaches such as phage display have had in identifying such markers by us

80 Antibody libraries and phage display have provided the key elements for the cre

81 led nerve-binding peptide, NP41, selected by phage display, highlights peripheral nerves in vivo.

82 We generated a phage-displayed human antibody V(H) domain library from

83 Smith reconstructs the story of the phage-display idea as he personally experienced it.

84 es to random library screening methods (e.g. phage display), in vitro cellular-based experiments and

85 Phage display is a key technology for the identification

86 Phage display is a powerful approach for evolving protei

87 Phage display is a powerful method for selecting affinit

88 Antibody phage display is a powerful platform for discovery of cl

89 Phage display is a powerful technology that selects spec

90 Phage display is a prominent screening technique with a

91 tide macrocycle that was recently evolved by phage display (Ki = 0.84 +/- 0.03 nM).

92 ers, we used H1N1pdm09 whole-genome-fragment phage display libraries (GFPDL) to evaluate the antibody

93 Here we used whole-genome gene fragment phage display libraries (GFPDLs) expressing peptides of

94 ogether these data suggest that selection of phage display libraries against a clonal progenitor stem

95 (>=14 days of shedding) using gene fragment phage display libraries and surface plasmon resonance.

96 Peptides were selected from 7- to 15mer phage display libraries by panning with hyaluronan-Sepha

97 Antibody phage display libraries combined with high-throughput se

98 at employs two genetically encoded substrate phage display libraries coupled with next generation seq

99 gy, which involved the use of random peptide phage display libraries coupled with next-generation seq

100 mmunized mice with ACT and screened antibody phage display libraries for binding to purified ACT.

101 e-borne peptidomimetics can be selected from phage display libraries in a straightforward systematic

102 Starting from large phage display libraries of single-chain antibody fragmen

103 port the engineering and characterization of phage display libraries of stable human VH domains and t

104 tides of 7 to 12 amino acids identified from phage display libraries using both bioinformatics-based

105 Whole genome-fragment phage display libraries, expressing linear and conformat

106 nst different conformations of betaarrs from phage display libraries.

107 ies have been detected by screening antibody phage display libraries.

108 nding of Salmonella to peptides derived from phage display libraries.

109 n-domain monobodies originally selected from phage-display libraries.

110 we use next-generation sequencing to analyze phage-displayed libraries and uncover a strong bias indu

111 selection of the scaffold surface to vary in phage display, libraries can be designed that present se

112 -exposed individuals by using a whole-genome phage display library (H7N7-GFPDL) to explore the comple

113 We have generated an immunized phage display library against ApoB-100 and isolated four

114 Here we describe the construction of a VHH phage display library against the cyanobacterial hepatot

115 sequence space of a given scaffold through a phage display library and by (ii) panning multiple libra

116 and other species was isolated from a human phage display library and engineered to contain an IgG1

117 A mutagenized substrate phage display library based on a 73-amino acid fragment

118 A synthetic phage display library based on the variable domain of ne

119 we constructed a chimeric chicken-human Fab phage display library comprising 10(10) variants targeti

120 Here, we utilize a NoV GI.1 Jun-Fos-assisted phage display library constructed from randomly fragment

121 cDNA, and cloned into a phagemid vector for phage display library construction.

122 A phage display library covering 10(9) unique dodecapeptid

123 rabbit antibody repertoire represented by a phage display library encompassing >10 billion independe

124 or intrathecal antiviral antibodies, using a phage display library expressing 481,966 overlapping pep

125 e inhibitory functions of C4S, we screened a phage display library for peptides binding to C4S.

126 primers were used to generate and assemble a phage display library from human CD160-vaccinated rats.

127 for many fields including immunodiagnostics, phage display library generation, and "humanness" assess

128 A 9-mer pVIII M13 phage display library is screened against U937 to identi

129 vel technique by screening fibrinogen with a phage display library of 3 billion random, conformationa

130 Here, we describe the first fully synthetic phage display library of humanized llama single domain a

131 A phage display library representing a highly diverse arra

132 Using a phage display library screen, we identified a peptide, P

133 ion phage display (NGPD) strategy, combining phage display library screening with next-generation seq

134 was identified by both Peptide Scanning and Phage Display Library screening, other approaches, such

135 In the current study, we use whole genome phage display library spanning the entire ZIKV genome (Z

136 in antibody (nanobody) isolated from a llama phage display library that confers potent neutralizing c

137 We have utilized a high-diversity phage display library to engineer antibody fragments (Fa

138 human single-chain variable fragment (scFv) phage display library was screened for binding, internal

139 specific binders were generated using a Fab phage display library with CBP-fused constructs.

140 faces facing the peritoneum, we subtracted a phage display library with female mouse peritoneum tissu

141 e identified through immunocreenings of a T7 phage display library with high accuracy, which may have

142 r three rounds of biopanning by 1E4 from the phage display library, a mimetic peptide, m1E41920, was

143 cterized HAIYPRH, from the M13-based Ph.D.-7 phage display library, as a propagation-related TUP resu

144 g immunoselection of random sequences from a phage display library, deep sequencing, and pattern anal

145 By screening a peptide phage display library, we discovered a novel ligand (PDN

146 Using a human fragment antigen-binding phage display library, we identified a human antibody te

147 By using phage display library, we identified two highly specific

148 By screening a phage display library, we previously identified a peptid

149 FVIII-specific scFv derived from a synthetic phage display library.

150 ning of a naive llama single-domain antibody phage display library.

151 , TPFDLRPSSDTR, which is identified by using phage display library.

152 nerated, characterized, and used to screen a phage display library.

153 towards LpxA was previously identified in a phage display library.

154 teome can be represented by a random peptide phage display library.

155 pertoires were elucidated by genome-fragment phage-display library analysis, and antibody avidities f

156 A phage-display library consisting of the VH H region cont

157 A1 binding was isolated from a combinatorial phage-display library constructed from a mite-allergic p

158 variable fragments (Fvs), and constructed a phage-display library containing Fvs that bind to the RI

159 We screened a phage-display library expressing the entire complement o

160 We isolated four distinct nanobodies from a phage-display library generated from an alpaca immunized

161 Reaction between M13 phage-displayed library of peptides terminated with an a

162 Such phage-displayed ligands offer useful reagents for biosen

163 cific progenitor cell-binding peptides using phage display may be hindered by the large cellular hete

164 The results also suggest that phage display may offer a useful approach for rapid inve

165 Here we describe a phage display method to directly screen for ligands that

166 for the infarct/border zone, we used in vivo phage display methods and an optical imaging approach: f

167 Two short peptides previously identified by phage display, named YSA and SWL, are widely used as Eph

168 d control samples confirmed a major issue in phage display, namely the selection of unspecific peptid

169 Here, using a next-generation phage display (NGPD) strategy, combining phage display l

170 opoulos et al. cleverly uses next-generation phage display (NGPD) to identify peptide ligands that bi

171 Here, we used next generation phage-display (NGPD) and a 2-proportion Z score analysis

172 a1 strand was discovered to be essential for phage display of a functional FHA1 domain.

173 ith native proteins and for the selection by phage display of in vivo-matured Nanobodies that bind co

174 Phage display offers a powerful approach to engineer pro

175 ning antibody variable domains, generated by phage display or derived from human/humanized monoclonal

176 preserves their individual identities (e.g., phage display or one-bead one-compound).

177 r for biotechnological applications, such as phage display, or because of their effect on the toxicit

178 set coupled with a streamlined strategy for phage display panning enable the rapid isolation and ide

179 that are superior to candidates derived from phage display panning experiments.

180 were generated against DT from two different phage display panning strategies using a human immune li

181 We utilised a novel phage display panning strategy to isolate a high affinit

182 performed myeloma cell surface screenings of phage-displayed patient transplant immunomes.

183 Phage display (PD) is frequently used to discover peptid

184 We have used the shotgun Phage Display (PD) technology to identify candidate prot

185 We discuss the contribution of phage display peptide libraries in determining dominant

186 g an aggregated mAb as bait for screening of phage display peptide library and identifying those pept

187 Previously, a phage display peptide library screen identified SM1, a p

188 Here we screened phage-displayed peptide libraries and identified the 13-

189 To demonstrate this, phage-displayed peptide libraries are developed that con

190 lic-peptide ligands for therapeutic targets, phage-displayed peptide libraries in which cyclization i

191 Towards this goal, we biopanned three phage-displayed peptide libraries on a series of well-de

192 As a proof of concept, we produced phage-displayed peptide libraries Ser-[X]4-Gly-Gly-Gly,

193 o study the affinity and binding kinetics of phages, displaying peptide libraries.

194 reds to thousands of synthetically generated phage display peptides exhibit variable and often-weak t

195 active targeting with nanoparticles bearing phage display peptides or cell-penetrating peptides and

196 Competitive immunoscreening of phage-displayed peptides was applied to select mimotopes

197 ptor, from a library of approximately 10(11) phage-displayed peptides, which binds PSMA with high aff

198 nding parameters of 26 different filamentous phages, displaying peptides selective for enhanced Green

199 Here, we used phage display phenotypic screening to isolate antibodies

200 ere, we performed proteome-wide programmable phage-display (PhIP-Seq) on sera from a cohort of people

201 We adapted a competitive peptide phage display platform to identify candidate peptides bi

202 In this work, we established a phage-display platform to select for specific amidation,

203 The extended phage display procedure provides a generic way to non-na

204 oped a dedicated approach, proteomic peptide-phage display (ProP-PD), to identify domain-SLiM interac

205 er of functionalities that can be encoded on phage-displayed proteins and provide a foundation to fur

206 y technology was used to screen a library of phage displaying random 12-mer peptides for those that b

207 e-containing tetrapeptides by constructing a phage-display random tetrapeptide library and conducting

208 In addition, epitope mapping with a phage-displayed random peptide library revealed that one

209 A phage-displayed recombinant antibody library was used to

210 We used random peptide phage display, reverse immunization, and next-generation

211 Phage-display scFv hybrid libraries of allergic donor-de

212 A phage display screen against EphA2, a receptor tyrosine

213 al Syp1 cargo-sorting motifs, we performed a phage display screen and used biochemical methods to dem

214 rthermore, another peptide from the original phage display screen, midgut peptide 2 (MP2), strongly i

215 Using an in vivo phage-display screen, we identify a peptide, targeted ax

216 Phage display screening allows the study of functional p

217 eptide (sequence CAQK) identified by in vivo phage display screening in mice with acute brain injury.

218 We therefore developed a platform for rapid phage display screening of deep recombinant libraries co

219 s study was to identify specific peptides by phage display screening to enable EpiSC specific cargo d

220 15-amino acid peptide (15-mer), isolated via phage display screening, targeted Abeta and attenuated i

221 (HAP) of 15 residues was identified through phage-display screening followed by saturation mutagenes

222 t very high throughput using systems such as phage display, screening for functional properties (e.g.

223 We performed in vivo peptide phage display screens in mice bearing 4T1 metastatic bre

224 e sequences that are typically identified in phage display screens published to date.

225 Based on the reactive loop sequences of the phage display-selected inhibitors, we recombinantly expr

226 ed protein (GRP78), a receptor that binds to phage-display-selected ligands, such as the SNTRVAP moti

227 Phage display selection and downstream characterization

228 target-unrelated peptide (TUP) can arise in phage display selection experiments as a result of a pro

229 Phage display selection followed by chemical optimizatio

230 In vivo phage display selection is a powerful strategy for direc

231 SHC]OH (TCP-1), a small peptide derived from phage display selection, for targeting human CRC xenogra

232 hains, catechols, and sequences derived from phage display selection.

233 Phage display selections against peptides were used to g

234 ic antibodies (sABs) generated by customized phage display selections against the fusion protein BRIL

235 in Escherichia coli and used as antigens in phage display selections using a synthetic human single-

236 selectively bind to CMG2, here we performed phage display selections using magnetic beads having bou

237 NT)-binding peptide motifs identified from a phage display selectively distinguish TNT down to 300 p.

238 cognized by a monoclonal antibody (3C3G3) by phage display, site-directed mutagenesis, and surface pl

239 Particularly, a critical element in phage display sorting is functional immobilization of ta

240 ng peptide (CBP) as an immobilization tag in phage display sorting.

241 A phage-display strategy is presented whereby approximatel

242 A (HlgA) and LukS genes into a custom-built phage display system, termed pComb-Opti8.

243 Using a novel phage display system, we discovered an adhiron that shar

244 terminal tail of bZIP28 were identified in a phage display system.

245 element (DGR) provides a naturally occurring phage-display system, but engineering efforts are hamper

246 e then subjected to in vitro selection using phage display technique and 3 clones (CSP3, CSP4 and CSP

247 of allergen mimotopes identified through the phage display technique.

248 cted from a random peptide library using the phage display technique.

249 to cysteine conjugation, we have invented a phage-display technique in which its displayed peptides

250 ed diagnostic and therapeutic agents, is the phage-display technique.

251 g a competitive inhibition strategy, we used phage display techniques to identify 53 single-chain var

252 IgG)4kappa- and IgG4lambda-Fab library using phage display technology and by Epstein-Barr virus trans

253 In this paper, we combined the phage display technology and electrochemical impedance s

254 Phage display technology enabled the selection of affini

255 Human phage display technology has revolutionized the process

256 vel treatment for these individuals, we used phage display technology to target the insulin receptor

257 Phage display technology was used to isolate monoclonal

258 In this study, phage display technology was used to screen a library of

259 Phage display technology was used to select affibody mol

260 Using phage display technology, Fynomers were generated inhibi

261 Using phage display technology, human antigen-binding fragment

262 Using phage display technology, we engineered the human IgG1 F

263 onisin B1 using a novel mimotope selected by phage display technology.

264 We selected Fab fragments using the phage display technology.

265 Taking advantage of phage-display technology, we engineered a fully human si

266 we generated high-affinity SUMO2 variants by phage display that bind the back side binding site of Ub

267 eukaryotic display technology comparable to phage display that would overcome the protein translatio

268 ized virtually toward any specific cancer by phage display, the angiogenin-binding phages are thus un

269 A naturally occurring analog to phage display, the Bordetella bronchiseptica bacteriopha

270 Here, we used phage display to develop specific ubiquitin-based inhibi

271 E and other pKal-mediated disorders, we used phage display to discover a fully human IgG1 monoclonal

272 next-generation sequencing-assisted antibody phage display to establish a highly myeloma-specific epi

273 Here, we used phage display to generate highly potent and selective ub

274 Here, we used phage display to generate PTH1R ECD-specific antibodies

275 We present the first report of the use of phage display to identify novel activities toward insect

276 We used phage display to isolate peptides that possess bona fide

277 Here, to further characterize HBeAg, we used phage display to produce a panel of chimeric rabbit/huma

278 cted-diversity combinatorial Fab library and phage display to rapidly generate synthetic antibodies (

279 We have used Phage Display to select scFv (single-chain variable frag

280 We randomized the hydrophobic core and used phage display to select variants that bound to each of t

281 tor 1 (TFPI1 D2) to directed evolution using phage display to yield inhibitors against human and rat

282 We used phage-display to produce a melanoma-specific TCR (alpha2

283 Furthermore, sensors composed of phage displaying trinitrotoluene (TNT)-binding peptide m

284 Phage-displayed tumor antigens were enriched by biopanni

285 We employed a phage-displayed ubiquitin variant (UbV) library to devel

286 TP4 was obtained by phage display using the four-repeat Tau construct K18Del

287 in fragment variable (scFv) was generated by phage display, using the extracellular domain of recombi

288 from their heavy-chain only antibodies in a phage display vector and selected nanobodies (VHHs) agai

289 Phage display was then used to identify single-chain var

290 Selection via phage display was used first to enrich the library betwe

291 Previously, a Fab against Rev generated by phage display was used to crystallize and solve the stru

292 Phage display was used to further enhance the affinity o

293 By using phage display we identified specific positions that clus

294 Through the use of a T7 phage display, we discovered a novel interaction between

295 With the aid of secretome phage display, we identified a highly conserved protein

296 Using structure-based design and phage display, we modified the initial inhibitors to gen

297 By using combinatorial phage display, we screened selected VH genes paired with

298 Using in vivo phage display, we searched for molecular markers of the

299 chain encoded by VH3-30, was isolated using phage display with immobilized hemagglutinin (HA) from i

300 ative high-throughput approach that combines phage display with second generation sequencing.